Orthoson has developed novel motion-restoring minimally invasive treatments for low back pain. The company is a spin-off of the University of Oxford’s Institute of Biomedical Engineering and has recently completed an £8.9m Series A fund round to help prepare its patent-protected product for Phase I trials in the US.

New international investors in this expanded round include our venture capital firm, as the lead investor, and the Chinese investment company Yonghua Capital. Plans for this investment include completion of preclinical safety studies, plus regulatory activity to prepare for US clinical trials expected to take place from 2024. This will be followed by European and international clinical trials supporting the global launch. With the completion of this Series A fundraising, OrthoSon’s Board will be strengthened as our partner, Aristos Doxiadis, and Mr. Wang Chong, Venture Partner at Yonghua Capital, join as Director and Observer respectively. Existing investors also participated in the financing.

Our partner Aristos Doxiadis said ‘We like to invest in companies which have strong technologies, teams and market positions, and OrthoSon has all of these. Big Pi Ventures believes its product will have a significant impact on the back pain market, improving quality of life for sufferers and reducing healthcare costs and disability.’

Read more about our portfolio company Orthoson here or visit their website.